Spot on.

First 1117 Last

Share
Profile

Follow
one day

370 Posts.

27

03/01/23

17:36

Post #: 65513703
Share

Originally posted by Jujovitu: ↑

Hey MTV. No I'm not having it both ways.

performance rights are arbitrarily set by management to award themselves more share in the company. Simple. They could set it at 1 cent expiring next week and award themselves another $1million in shares. Yes an exaggerated example but it illustrates my point. This arbitrary setting of free share giveaways is something thats outta control. Management see the bright future thanks to the EV revolution and are frantically grabbing as much company equity as possible at the expense of the honest investor. It's crystal clear. Charles is a major shareholder and can almost certainly keep giving himself and his closest free shares.

Damn I wish I could give myself millions in the company I work for just for doing my job.

lets not forget this is not a new company. They've been around for years and years. The only reason Charles is still in the position is because of the investors. The history of VMT is not a particularly good one. It wasn't long ago that the company was on its last breaths. The rising tide by the EV revolution rose the VMT boat. The proliferation of EV manufactures is the proof. VMT have not capitalised on their perceived manufacturing advantage and have depended on 3rd parties like Super Soco to provide a finished, marketable, mass market product for them sell. When Stash bikes are selling 20,000 units a month then I'll shut up, but we all know at this rate we'll all be dead by then.

yes I'm frustrated and I will hold my shares for now. But absolutely they are taking the pi$$. Any suggestion otherwise is either denialism or plan ignorance. Just Mho.

Expand

Spot on.

VMT Price at posting: 39.5¢ Sentiment: Hold Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

There are more pages in this discussion • 1,174 more messages in this thread...

First 1117 Last

Add VMT (ASX) to my watchlist

(20min delay)
Last 12.5¢		Change 0.000(0.00%)		Mkt cap ! $52.27M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
1	409	12.0¢

Sellers (Offers)

Price($)	Vol.	No.
12.5¢	230743	5

View Market Depth

No.	Vol.	Price($)
1	409	0.120
4	101890	0.115
2	70000	0.110
2	58257	0.105
2	16500	0.100

Price($)	Vol.	No.
0.125	230743	5
0.130	447698	5
0.135	94459	2
0.140	572189	3
0.145	112654	3

Last trade - 16.12pm 07/10/2024 (20 minute delay)

VMT (ASX) Chart

Day chart unavailable

Spot on.

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Spot on.

Top Stories

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News